When Bristol Myers Squibb originally unveiled pivotal data for Breyanzi in second-line large B-cell lymphoma (LBCL) a year ago, a key weak point was a short follow-up time in the study. Now, the New York pharma is cranking up its CAR-T rivalry against Gilead Sciences with updated results.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,